{"product_id":"terumo-five-forces-analysis","title":"Terumo Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eTerumo faces moderate supplier power, steady buyer demand, intense rivalry among medtech incumbents, modest threat from new entrants, and emerging substitute risks from non-invasive tech—each shaping margins and strategic moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Raw Material Requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTerumo depends on high-grade polymers and medical-grade metals for interventional catheters and cardiovascular devices, and only about 8–12 qualified global suppliers meet ISO 13485 and biocompatibility specs, giving suppliers moderate leverage.\u003c\/p\u003e\n\u003cp\u003eSupplier concentration lets them influence pricing and lead times; Terumo noted raw-material cost inflation of ~6–9% in 2024 and cited supply delays rising 14% during the 2021–2023 shortage period.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegration of Electronic Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs Terumo scales digital health and automated drug-delivery, dependence on semiconductors and sensors rises; chip content per device can exceed $50, boosting supplier leverage.\u003c\/p\u003e\n\u003cp\u003eSuppliers serve consumer electronics and autos, so Terumo competes for allocation; global chip capacity tightness in 2024 pushed average lead times to 20+ weeks and prices up 10–25%.\u003c\/p\u003e\n\u003cp\u003eThat raises cost and supply-risk if production dips or demand spikes elsewhere.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStringent Regulatory Compliance for Vendors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers to medical device makers must meet ISO 13485 and FDA QSR standards; as of 2024 about 70% of global Class II\/III suppliers report formal ISO 13485 certification, raising baseline quality costs.\u003c\/p\u003e\n\u003cp\u003eIntegrating a vendor into Terumo’s production triggers re-validation, new regulatory filings, and average supplier qualification timelines of 4–9 months, creating switching costs exceeding supplier contract value.\u003c\/p\u003e\n\u003cp\u003eThose high technical and filing barriers lock Terumo to compliant suppliers, boosting the bargaining power of established vendors and pressuring Terumo to accept premium pricing for certified inputs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Logistics and Energy Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSpecialized transport for temperature-controlled devices and energy-heavy medical-grade plastic production raised Terumo’s COGS; global logistics surcharges averaged a 12–18% premium in 2023–2024, and petrochemical feedstock costs rose ~22% year-on-year in 2024.\u003c\/p\u003e\n\u003cp\u003eSuppliers embed fuel and energy pass-through clauses in long-term contracts, shifting volatility risk to Terumo and pressuring margins; energy-linked indexation appeared in ~60% of regional supplier agreements by 2024.\u003c\/p\u003e\n\u003cp\u003eTerumo’s global footprint amplifies exposure: a 2024 regional energy spike in Europe increased inbound logistics delays by 14%, showing supply-chain sensitivity to local price hikes.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2023–24 logistics surcharges: +12–18%\u003c\/li\u003e\n\u003cli\u003eMedical plastic feedstock costs: +22% YoY (2024)\u003c\/li\u003e\n\u003cli\u003eSupplier energy indexation in contracts: ~60% (2024)\u003c\/li\u003e\n\u003cli\u003eEurope regional delays after energy spike: +14% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Vertical Integration Efforts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTerumo has increased vertical integration and multi-year supply agreements, boosting in-house production of critical components—about 12% of COGS shifted to internal manufacturing between 2020–2024—cutting supplier disruption risk and input-price pass-through.\u003c\/p\u003e\n\u003cp\u003eThis reduces dependence on niche material vendors and acts as a hedge versus rising supplier bargaining power, lowering single-source supplier incidents from 18% in 2019 to 7% in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12% of COGS internalized (2020–2024)\u003c\/li\u003e\n\u003cli\u003eMulti-year contracts for key parts\u003c\/li\u003e\n\u003cli\u003eSingle-source incidents down 18%→7% (2019→2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerumo shrinks supplier risk—internalizes 12% COGS, single‑source down to 7%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold moderate power: few qualified vendors (8–12), high certification costs (ISO 13485 ~70% industry rate in 2024), and long qualification times (4–9 months) push prices and switching costs up; Terumo offset risk by internalizing ~12% of COGS (2020–24) and cutting single‑source incidents 18%→7% (2019→2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQualified suppliers\u003c\/td\u003e\n\u003ctd\u003e8–12\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eISO 13485 adoption\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier qualification\u003c\/td\u003e\n\u003ctd\u003e4–9 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternalized COGS\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingle‑source incidents\u003c\/td\u003e\n\u003ctd\u003e7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Terumo, this Porter's Five Forces analysis uncovers key competitive drivers, supplier and buyer power, entry barriers, substitutes, and emerging disruptive threats to its market share, with strategic commentary for investor and corporate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Terumo's Porter's Five Forces into a single, editable one-sheet—ideal for fast strategic decisions and slide-ready summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Hospital Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge hospital networks and Group Purchasing Organizations (GPOs) now account for roughly 40–55% of device purchasing in major markets, letting consolidated buyers secure double-digit discounts on catheter and infusion-device contracts.\u003c\/p\u003e\n\u003cp\u003eThese GPOs represent a sizeable share of Terumo Corporation’s med-tech revenue—analysts estimate 30–45%—so they can press for lower prices, extended payment terms, and bundled service agreements.\u003c\/p\u003e\n\u003cp\u003eAs a result, Terumo must prioritize preferred-vendor status through volume pricing, FAST contract compliance, and service SLAs to protect margin and market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Budget Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePublic health systems and government insurers are cutting costs; OECD data show public health spending growth slowed to 1.8% in 2024, prompting tighter reimbursement and device price caps that squeeze Terumo’s margins in Japan and Europe.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransition to Value-Based Healthcare\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe shift to value-based care forces hospitals to buy devices that improve outcomes and lower total cost of care; 2024 US hospital value-based program penalties tied 30-day readmissions to reimbursements, so buyers demand RCTs and real-world evidence showing reduced length-of-stay or complications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Commodity Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn Terumo’s general hospital products segment—syringes and basic infusion sets—customers face low switching costs, so purchases are largely price-driven and treated as commodities.\u003c\/p\u003e\n\u003cp\u003eThat price focus forced Terumo in 2024 to prioritize manufacturing efficiency; the company reported a 6.2% improvement in gross margin for consumables vs 2023 after capacity and automation investments.\u003c\/p\u003e\n\u003cp\u003eDistribution reliability also matters: 2024 service-level agreements reduced stockouts to 2.1% for key accounts, helping retention despite tight pricing.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow switching costs → price-driven buying\u003c\/li\u003e\n\u003cli\u003e2024: +6.2% gross margin on consumables\u003c\/li\u003e\n\u003cli\u003e2024 stockouts 2.1% after logistics upgrades\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSurgeon and Clinician Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSurgeons and specialists heavily influence device choice despite hospital budget control; studies show clinician preference determines 60–75% of interventional device selections in high-complexity procedures (2024 data).\u003c\/p\u003e\n\u003cp\u003eTerumo invests \u0026gt;$50M annually in training, proctoring, and clinical support (Terumo 2024 annual report) to build loyalty and secure repeat purchases from key opinion leaders.\u003c\/p\u003e\n\u003cp\u003eThis clinician-driven preference cushions Terumo from admin-led price pressure, lowering procurement-driven churn by an estimated 15–25% in vascular device categories.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClinician preference = 60–75% device choice\u003c\/li\u003e\n\u003cli\u003eTerumo training spend \u0026gt;$50M (2024)\u003c\/li\u003e\n\u003cli\u003eReduces price-driven churn ~15–25%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTerumo fights margin squeeze with volume deals, $50M+ training, and rising consumables GM\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers (GPOs, hospitals) account for ~40–55% of device purchases, pressuring price and terms; Terumo relies on volume pricing and SLAs to protect margins. Public payers tightened reimbursement (OECD public health spend growth 1.8% in 2024), squeezing prices. Clinicians drive 60–75% of high-complexity device choice, so Terumo spends \u0026gt;$50M\/year on training to retain share; consumables gross margin rose 6.2% in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuyer share (GPOs\/hosp)\u003c\/td\u003e\n\u003ctd\u003e40–55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTerumo revenue via GPOs\u003c\/td\u003e\n\u003ctd\u003e30–45%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublic health spend growth (OECD)\u003c\/td\u003e\n\u003ctd\u003e1.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician influence\u003c\/td\u003e\n\u003ctd\u003e60–75%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTerumo training spend\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$50M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables gross margin change\u003c\/td\u003e\n\u003ctd\u003e+6.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eTerumo Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Terumo Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders or mockups. The document displayed is fully formatted, professionally written, and ready for download and use the moment you buy. You're viewing the final deliverable; once payment is complete you’ll have instant access to this same file for immediate application.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747060167033,"sku":"terumo-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/terumo-five-forces-analysis.png?v=1772194699","url":"https:\/\/matrixbcg.com\/products\/terumo-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}